IDegLira was generally well tolerated ; fewer participants in the IDegLira group than in the liraglutide group reported gastrointestinal adverse events ( nausea 88 vs 197 % ) , although the insulin degludec group had the fewest participants with gastrointestinal adverse events ( nausea 36 % ) .